We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.07 | -0.07% | 97.27 | 97.91 | 97.07 | 97.75 | 1,045,674 | 01:00:00 |
From May 2019 to May 2024
0757 GMT - Shares in Novartis rise 2.1% to CHF81.85 after the company released 2Q earnings which Berenberg describes as "a solid set of Q2 numbers". It points to "strength in pharma driven by key growth engines, while Alcon has shown a welcome return to top-line growth." The company "should be on a sustainable growth trajectory," it says. Berenberg has a price target of CHF85. Novartis reported a slight rise in 2Q net income, to $1.98 billion from $1.81 billion, while sales fell 2% to $12.24 billion. Proceeds from divestments helped offset its heavier investment into the launch of new drugs that it hopes will compensate the decline of its best-selling cancer drug Gleevec. Analysts had expected Novartis to post net income of $1.83 billion and revenue of $12.26 billion. (jessica.fleetham@wsj.com)
(END) Dow Jones Newswires
July 18, 2017 04:12 ET (08:12 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
